ScienceVest Weekly Deal

Sign up below to receive a weekly science / frontier-tech deal to your inbox

Deals come vetted and diligenced by our scientific diligence network

Diligence Network

Comprised of world-renowned scientists and dozens of PhD's from across the globe

Aubrey de Grey

Aubrey de grey profile f1890dd6624beb1121bd337922b9237fa5aa522f43aa9f6351d9a605cd880879

  • Chief Science Officer SENS Foundation
  • Editor-in-chief of the academic journal Rejuvenation Research
  • Author of The Mitochondrial Free Radical Theory of Aging (1999)
  • Co-author of Ending Aging (2007)

Elizabeth Irons

Elizabeth irons profile 40a0a3632a95408fd981b1e724a1bc3b8a60bf83a7d72ede74e43f6cf9770f22

  • Founder & CEO of Science Exchange
  • Partner at YCombinator
  • Active angel investor
  • Studied at The Institute of Cancer Research

Michael Benzinou

Michael benzinou profile 63e2fcc34848d7aae5db1759a357188ff01d4c56deb8a17a3ef90821a4cac6a9

  • Licensing and Business Development UCSF
  • Molecular Biologist - Genetics and Genomics University of California, San Francisco
  • Postdoctorate Fellow Institut Pasteur
  • UCSF Lean Launchpad - Digital Health Track

Deal Flow

Sourced directly from investor network, top incubators, top University TTO's and more

Y Combinator

Ycombinator profile 419dc46de8ee59223fffde8f115bceb0b76909fac509777c3f4d600100dc707f

NSF ICorps

Nsf icorps profile 8b8a9aea819156e6d399be5f4ba73d198826aac428987c3a106c5dd7fd007103

Kauffman Fellows

Kauffman fellows profile b217675fb44466c2e6d6950a25f1659c49d534e83420c936cebaab4e060eb718

Just 1 deal per week, we promise!

Sign up below

Sciencevest © 2016

This site is operated by ScienceVest Inc.,"ScienceVest", which is not a registered broker-dealer. ScienceVest does not give investment advice, endorsement, analysis or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. ScienceVest has not taken any steps to verify the adequacy, accuracy, or completeness of any information. Neither ScienceVest nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy or completeness of any information on this site of the use of information on this site.

This website is intended solely for accredited investors. Investments in private placements and startup investments in particular are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted stock that may be subject to holding period requirements. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.